HSV-2 vaccine: current status and insight into factors for developing an efficient vaccine
- PMID: 24469503
- PMCID: PMC3939461
- DOI: 10.3390/v6020371
HSV-2 vaccine: current status and insight into factors for developing an efficient vaccine
Abstract
Herpes simplex virus type 2 (HSV-2), a globally sexually transmitted virus, and also one of the main causes of genital ulcer diseases, increases susceptibility to HIV-1. Effective vaccines to prevent HSV-2 infection are not yet available, but are currently being developed. To facilitate this process, the latest progress in development of these vaccines is reviewed in this paper. A summary of the most promising HSV-2 vaccines tested in animals in the last five years is presented, including the main factors, and new ideas for developing an effective vaccine from animal experiments and human clinical trials. Experimental results indicate that future HSV-2 vaccines may depend on a strategy that targets mucosal immunity. Furthermore, estradiol, which increases the effectiveness of vaccines, may be considered as an adjuvant. Therefore, this review is expected to provide possible strategies for development of future HSV-2 vaccines.
Figures


Similar articles
-
Estradiol Enhances Antiviral CD4+ Tissue-Resident Memory T Cell Responses following Mucosal Herpes Simplex Virus 2 Vaccination through an IL-17-Mediated Pathway.J Virol. 2020 Dec 9;95(1):e01206-20. doi: 10.1128/JVI.01206-20. Print 2020 Dec 9. J Virol. 2020. PMID: 33028712 Free PMC article.
-
Current status and prospects for development of an HSV vaccine.Vaccine. 2014 Mar 20;32(14):1553-60. doi: 10.1016/j.vaccine.2013.08.066. Epub 2013 Sep 6. Vaccine. 2014. PMID: 24016811 Free PMC article.
-
Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.J Virol. 2017 Apr 13;91(9):e02257-16. doi: 10.1128/JVI.02257-16. Print 2017 May 1. J Virol. 2017. PMID: 28228587 Free PMC article.
-
Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development.Vaccine. 2019 Nov 28;37(50):7363-7371. doi: 10.1016/j.vaccine.2017.09.044. Epub 2017 Sep 25. Vaccine. 2019. PMID: 28958807 Free PMC article. Review.
-
Vaccines for Herpes Simplex: Recent Progress Driven by Viral and Adjuvant Immunology.Methods Mol Biol. 2020;2060:31-56. doi: 10.1007/978-1-4939-9814-2_2. Methods Mol Biol. 2020. PMID: 31617171 Review.
Cited by
-
Antiviral Activity of Tannic Acid Modified Silver Nanoparticles: Potential to Activate Immune Response in Herpes Genitalis.Viruses. 2018 Sep 26;10(10):524. doi: 10.3390/v10100524. Viruses. 2018. PMID: 30261662 Free PMC article.
-
CCL19 and CCR7 Expression, Signaling Pathways, and Adjuvant Functions in Viral Infection and Prevention.Front Cell Dev Biol. 2019 Oct 1;7:212. doi: 10.3389/fcell.2019.00212. eCollection 2019. Front Cell Dev Biol. 2019. PMID: 31632965 Free PMC article. Review.
-
What's new in HIV dermatology?F1000Res. 2019 Jun 28;8:F1000 Faculty Rev-980. doi: 10.12688/f1000research.16182.1. eCollection 2019. F1000Res. 2019. PMID: 31297183 Free PMC article. Review.
-
Vaccination against infectious diseases: what is promising?Med Microbiol Immunol. 2014 Dec;203(6):365-71. doi: 10.1007/s00430-014-0346-1. Epub 2014 Jul 27. Med Microbiol Immunol. 2014. PMID: 25064610 Review.
-
Herpes simplex virus type 2 in sub-Saharan Africa and the potential impact of helminth immune modulation.Front Cell Infect Microbiol. 2024 Dec 4;14:1471411. doi: 10.3389/fcimb.2024.1471411. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 39698320 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources